Misplaced Pages

Stiff-person syndrome: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 19:25, 15 February 2007 editQrater (talk | contribs)91 edits Symptoms and prognosis← Previous edit Revision as of 19:30, 15 February 2007 edit undoQrater (talk | contribs)91 edits TreatmentNext edit →
Line 25: Line 25:


==Treatment== ==Treatment==
Treatment is mostly ] with muscle relaxants such as ], which lose their effectiveness as the illness progresses. Because many patients with SPS have circulating antibodies to ], an ] cause of the disease has been postulated. In the absence of ], ]-controlled ] to determine treatment efficacy, some authorities recommend humane trials of ] therapy, ] or ] ] infusion. Treatment is mostly ] with muscle relaxants which enhance ] production such as ], which lose their effectiveness as the illness progresses.
In the absence of ], ]-controlled ] to determine treatment efficacy, some authorities recommend humane trials of ] therapy, ] or ] ] infusion.


==References== ==References==

Revision as of 19:30, 15 February 2007

Medical condition
Stiff-person syndrome
SpecialtyNeurology Edit this on Wikidata
Frequency8e-05%

Stiff person syndrome (SPS) (or occasionally, stiff-man syndrome) is a rare neurologic disorder of unknown etiology.

History

SPS was first described by Moersch and Woltman at the Mayo Clinic in 1956 .

Symptoms and prognosis

Those with the illness experience progressive, fluctuating tonic contractions of all muscles, particularly the axial musculature. An inability to walk and general paralysis quickly follow; death usually occurs six to twelve months after diagnosis.

MRI detection of GABA in the brain have demonstrated reduced levels in stiff-person syndrome.

Treatment

Treatment is mostly palliative with muscle relaxants which enhance GABA production such as benzodiazepines, which lose their effectiveness as the illness progresses. In the absence of double-blind, placebo-controlled class A trials to determine treatment efficacy, some authorities recommend humane trials of immunosuppressive therapy, plasmapheresis or intravenous immunoglobulin infusion.

References

  • MOERSCH FP, WOLTMAN HW (1956). "Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observations in 13 other cases". Mayo Clin Proc. 31 (15): 421–7. PMID 13350379.
  • Murinson BB (2004). "Stiff-person syndrome". Neurologist. 10 (3): 131–7. PMID 15140273.

See also

External links

Categories: